Galapagos appoints Bart Filius as President and Chief Operating Officer
24 Marzo 2021 - 9:01PM
Galapagos appoints Bart Filius as President and Chief Operating
Officer
Mechelen, Belgium; 24 March 2021; 21.01
CET; Galapagos (Euronext & Nasdag; GLPG) announced today that
its Supervisory Board has promoted Bart Filius to President and
Chief Operating Officer (COO). Going forward, CEO Onno van de
Stolpe will maintain oversight of the research and development
activities, while Bart Filius will take responsibility for business
development, commercial strategy, finance, human resources, and
other business operations.
Bart Filius joined Galapagos in 2014 as Chief
Financial Officer and subsequently took on the responsibility as
COO in 2017. During these years, Bart managed the substantial
growth of the company, successfully conducted the Nasdaq IPO, and
played a leading role in the negotiations for the R&D
partnership with Gilead.
Prior to joining Galapagos, Bart spent 13 years
at Sanofi, where he had leadership roles of increasing
responsibility in finance, country management and M&A. In his
early career, Bart was a strategy consultant at Arthur D. Little.
Bart holds an MBA from INSEAD.
Commenting on the promotion, CEO Onno van de
Stolpe said, “I’m delighted that Bart will take up this new role.
He has been instrumental in transforming Galapagos into a fully
integrated biotech, and he has proven that he has outstanding
strategic vision, business acumen, and leadership skills. Going
forward, I want to give my full attention to research and
development and our strategy to develop first-in-class medicines
based on the discovery of novel targets.”
Bart Filius added, “I’m highly energized by the
opportunity to lead Galapagos into the future, together with Onno
and the Management Board. We are in the midst of launching our
first commercial product and are preparing for future indications.
Galapagos is very keen to broaden its portfolio through smart
business development and has the financial resources to do so. To
achieve our goals, our business operations need to run smoothly. I
look forward with confidence to working on these 3 priorities with
the talented team of people that we have on board. These are
challenging but exciting times for Galapagos.”
About GalapagosGalapagos NV
discovers and develops small molecule medicines with novel modes of
action, several of which show promising patient results and are
currently in late-stage development in multiple diseases. Our
pipeline comprises Phase 3 through to discovery programs in
inflammation, fibrosis, and other indications. Our ambition is to
become a leading global biopharmaceutical company focused on the
discovery, development, and commercialization of innovative
medicines. More information at www.glpg.com.
Contacts
Investors: Elizabeth Goodwin VP Investor Relations
+1 781 460 1784
Sofie Van Gijsel Senior Director Investor Relations +32 485 19
14 15 ir@glpg.com
Media: Carmen Vroonen Global Head
Communications & Public Affairs +32 473 824 874
Kyra ObolenskySenior Director Corporate Communications +32 491
92 64 35
communications@glpg.com
Galapagos Forward-Looking Statements
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, that are subject to risks,
uncertainties and other factors that could cause actual results to
differ materially from those referred to in the forward-looking
statements and, therefore, the reader should not place undue
reliance on them. These risks, uncertainties and other factors
include, without limitation, that Galapagos may not be successful
in implementing its strategy to develop first-in-class medicines
based on novel target discovery, the inherent risks associated with
regulatory approval requirements (including that future indications
for our first commercial product may not be approved due to safety,
efficacy or other reasons) and that Galapagos may not be able to
successfully complete business development transactions, as well as
those risks and uncertainties identified in our Annual Report on
Form 20-F for the year ended 31 December 2019 and our subsequent
filings with the SEC. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. The forward-looking statements contained herein are
based on management’s current expectations and beliefs and speak
only as of the date hereof, and Galapagos makes no commitment to
update or publicly release any revisions to forward-looking
statements in order to reflect new information or subsequent
events, circumstances or changes in expectations.
Grafico Azioni Galapagos (EU:GLPG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Galapagos (EU:GLPG)
Storico
Da Apr 2023 a Apr 2024
